SFDA To Segregate Responsibilities Of Drug Administration, Appraisal And Approval
This article was originally published in PharmAsia News
Executive Summary
According to its recently published reorganization plan, China's State FDA will spread the control of drug administration, appraisal and approval into different bureaus. For instance, a new food permission bureau will be set up to exclusively approve food, cosmetics and healthcare products, while other bureaus will manage related responsibilities. In addition, SFDA will transfer the jurisdiction of technology appraisal on drug and medical devices to its lower level institutions, the National Institute for the Control of Pharmaceutical and Biological Products, Chinese Pharmacopoeia Commission, Center for Drug Evaluation and Medical Devices Evaluation Center. SFDA will now approve and supervise healthcare products. The constant policy revision means imminent change in the industry's product brand names, R&D and classification. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.